[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100474760":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":32,"centralContacts":37,"locations":21,"responsibleParty":43,"collaborators":46,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":59,"maxAge":21,"enrollmentInfo":60,"targetDuration":21,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":21,"overallStatus":69,"whyStopped":21,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":21},{"fullName":5,"class":6},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Additional sequences with MRCP+ and LiverMultiscan","PSC patients that undergo annual, standard care, MRI of the liver and MRCP will undergo additional Liver Multiscan sequences, taking approximately 15 minutes. After the MRI is performed, post-processing analysis named MRCP+ and LiverMultiscan will be performed without patient involvement.",[12,13,14],"Device: Liver Multiscan sequences","Device: Liver Multiscan analysis","Device: MRCP+",[16,22,28],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DEVICE","Liver Multiscan sequences","Additional Liver Multiscan sequences will be performed after the MRI liver with MRCP is performed, taking approximately 15 minutes.",[9],null,{"type":17,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"Liver Multiscan analysis","Post processing tool (Software) for determining the corrected T1 time after the additional LMS sequences at baseline are performed. This cT1 reflects the activity of inflammation\u002Ffibrosis of the liver. Patient involvement is not necessary during this procedure.",[9],[27],"LMS",{"type":17,"name":29,"description":30,"armGroupLabels":31,"otherNames":21},"MRCP+","Post processing tool (Software) for quantifying MRCP images after the MRCP from follow up is performed. Patient involvement is not necessary during this procedure.",[9],[33],{"name":34,"affiliation":35,"role":36},"Cyriel Ponsioen, Prof MD PhD","Gastroenterologist and hepatologist","PRINCIPAL_INVESTIGATOR",[38],{"name":39,"role":40,"phone":41,"phoneExt":21,"email":42},"Tim E Middelburg, MSC","CONTACT","+31648510414","t.e.middelburg@amsterdamumc.nl",{"type":36,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"C.Y. Ponsioen","Principal Investigator",[47],{"name":48,"class":49},"Perspectum","INDUSTRY","100474760","clinical-application-of-annual-liver-multiscan-and-mrcp-in-primary-sclerosing-cholangitis-100474760",false,"NCT05462093","Clinical Application of Annual Liver Multiscan and MRCP+ in Primary Sclerosing Cholangitis","Clinical Application of Annual Liver Multiscan and MRCP+ in Primary Sclerosing Cholangitis: the CATCH-IT Study","CATCH-IT","Inclusion Criteria:\n\n* Established PSC diagnosis according to the IPSCSG definitions\n* Age ≥ 18\n* Able to give informed consent\n\nExclusion Criteria:\n\n* Post LTx\n* Known allergy for MRI contrast agents, implants non-compatible with MRI or extreme claustrophobia causing discontinuation of MRI studies.","ALL","18 Years",{"count":61,"type":62},200,"ESTIMATED","INTERVENTIONAL",[65],"NA","Primary sclerosing cholangitis (PSC) is a chronic progressive biliary disease that affects approximately 1200 patients in the Netherlands and around 80,000 in the Western world. It is often accompanied by ulcerative colitis (UC) or Crohn's disease affecting the large bowel. The cause of PSC is unknown, there is no medical therapy available that has proven to halt disease progression and the median time until death or liver transplantation is 13-21 years.\n\nDiagnosis is made by magnetic resonance cholangiography (MRC), or in the case of so called small duct disease by liver biopsy.\n\nDue to the heterogeneous disease course and the relatively low clinical event rate of 5% per year it is difficult to predict prognosis of individual patients or to recommend any surveillance strategy for malignancies. Also, the lack of surrogate endpoints impedes performing clinical research. Recently, two new post-processing tools have been developed to characterize and quantify abnormalities in the biliary tree as well as excretory function captured by MRC. These tools called MRCP+ (quantitative magnetic resonance cholangiopancreatography +) and LiverMultiscan (LMS) hold the prospect of adequately depicting and quantifying lesions of the biliary tree as well as capturing functional derailment. However, several features must be tested before the utility of this tools in clinical patient care can be concluded. Therefore, the aim of this study is to investigate the utility of these novel techniques in monitoring disease activity by performing consecutive annual MRI's.",[68],"Primary Sclerosing Cholangitis","NOT_YET_RECRUITING","2022-07-13",{"date":72,"type":73},"2022-07-18","ACTUAL",{"date":75,"type":62},"2022-07",{"date":77,"type":62},"2029-07",{"name":5,"class":6}]